强化瑞舒伐他汀治疗对急性冠脉综合征患者PCI术后hsCRP的影响
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2013年第3期
- 页码:
- 353-355
- 栏目:
- 临床研究
- 出版日期:
- 2013-06-25
文章信息/Info
- Title:
- Effects of rosuvastatin on hsCRP in patients with acute coronary syndrome undergoing PCI
- Author(s):
- LI Yong qin; HAO Guang hua; ZHANG Chun yan; QIN Xiao jin; LUAN Chun hong; FAN Yan mei
- (Department of Cardiology, Second Hospital, Xi’an Jiaotong University, Xi’an 710004, Shaanxi, China)
- 关键词:
- 瑞舒伐他汀; 经皮冠状动脉介入治疗; 高敏C反应蛋白; 强化治疗
- Keywords:
- rosuvastain; percutaneous coronary intervention; highsensitivity creactive protein; intensive treatmeat
- 分类号:
- R541.4
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的:观察强化瑞舒伐他汀治疗对急性冠脉综合征患者经皮冠状动脉介入治疗(PCI)术后不同时间点高敏C反应蛋白(hsCRP)的影响。方法:选择2011年7月～2012年6月在我院诊断为急性冠脉综合征患者86例，随机分为2组。强化组于PCI术前服用瑞舒伐他汀20 mg/d，术后持续1周，1周后减量为10 mg/d。对照组PCI术前术后均为10 mg/d。分别于术前、术后1 d、术后1周，术后1个月检测患者血浆中hsCRP的变化。结果:强化组患者PCI术后1 d、术后1周血浆hsCRP的水平明显低于对照组，而PCI术后1个月两组患者血浆hsCRP的水平无显著差异。结论:PCI术前及术后1周应用瑞舒伐他汀20 mg/d较10 mg/d能够明显降低血浆hsCRP水平，且安全性良好。
- Abstract:
- AIM:To study the effects of rosuvastain at different dosages on serum hsCRP in patients with acute coronary syndrome undergoing PCI. METHODS: Fiftyeight patients were randomly divided into two groups: experiment group was given rosuvastain 20 mg/d before PCI and one week after PCI and control group was given rosuvastain (10 mg/d) before and after PCI. Serum hsCRP at different time points (before PCI, 1 day after PCI, 1 week after PCI and 1 month after PCI) was detected. RESULTS: One day and one week after PCI, the level of serum hsCRP of patients in experiment group was significantly lower than that in control group (P<0.01) but no significant difference in serum hsCRP was seen at 1 month after PCI. CONCLUSION: Rosuvastain at the dosage of 20 mg/d before PCI and one week after PCI can better decrease the level of serum hsCRP than rosuvastain at the dosage of 10 mg/d in patients with acute coronary syndrome undergoing PCI.
参考文献/References
[1]Link A,Ayadhi T,Bhm M,et al.Rapid immunanodulation by rosuvastatin in patients with acute coronary syndromes[J].Eur Heart J,2006,27(24):2945-2955.
[2]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention results of the ARMYDA ACS randomized trial[J].J Am Coll Cardiol,2007,49(12):1272-1278.
[3]Jones PH,Davidson MH,Stein EA,et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin,sinvastatin,and pravastatin across doses (STELLAR Trial)[J].Am J Cardial,2003,92(2):152-160.
[4]Hunninghake DB,Stein EA,Bays HE,et al.Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hightriglyceridemia[J].Coron Atery Dis,2004,15(2):115-123.
[5]瑞舒伐他汀中国注册临床研究协作组.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机、双盲、多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211.
[6]Nissen SE,Nicholls SJ,Sipahi L,et al.Effect of very high intensity stalin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J].JAMA,2006,295(13):1556-1565.
[7]Sipahi I,Tuzcu EM,Schoenhagen P,et al.Paradoxical increase in lumen size during progression of coronary atherosclerosis observation from the REVERSAL trial[J].Atherosclerosis,2006,189(1):229-235.
[8]Yun KH,Jeong MH,Oh SK,et al.The beneficial effect of high loading doses of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J].Int J Cardiol,2009,137 (3):246-251.
[9]廖玉华.经皮冠状动脉介入治疗术前的负荷剂量他汀类药物治疗[J].临床心血管病杂志,2011,27(1):1-2.
备注/Memo
- 备注/Memo:
- 收稿日期：2012-10-17.
作者简介：李永勤,副主任医师，博士 Email：wsxlyq@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed840
- 评论/Comments
